IRIS Ventures leads $15M into Innerskin to scale clinics EU-wide.

IRIS Ventures has led a $15 million investment into Paris-born medical-aesthetics group Innerskin, providing capital and sector expertise to accelerate clinic roll-out and broaden its medical-grade product offering. The round also included participation from existing backers such as Label Capital.

Founded in 2022 by Chrystelle Eid, Innerskin has expanded rapidly — opening 19 centres in France within three years — by combining non-invasive treatments with a physician-led, prevention-focused skincare line. The new funding is earmarked to scale the clinic footprint, strengthen the brand’s omni-channel patient journey and deepen investment in clinical R&D and staff training.

From a market perspective, Europe’s demand for accessible, physician‑led aesthetic care is rising sharply. Industry estimates place the global medical-aesthetics market in the low‑double‑digit billions today, with mid‑single‑digit to double‑digit percentage annual growth expected as consumers favour preventive, non‑surgical options and premium, science-backed skincare. For a chain like Innerskin, combining in‑clinic services with own‑label, medical‑grade products creates recurring revenue potential and higher lifetime customer value.

Chrystelle Eid said the partnership gives the brand “the operational support and capital to professionalise systems and replicate the model across new European markets.” From the investor side, Montse Suárez, founder and managing partner at IRIS Ventures, emphasised the team and category fit: “We back consumer health brands that can scale clinic economics and product revenue streams simultaneously,” she said. Celia Bosch, partner at IRIS Ventures, highlighted shifting consumer preferences towards transparent, clinically‑validated self‑care as a structural tailwind for the business.

Operationally, the capital will likely be deployed across three fronts: roll‑out of new sites in target European cities; expansion and regulatory preparation of the medical‑grade skincare range; and strengthening central systems for training, patient outcomes and digital bookings. That playbook mirrors successful rollouts in adjacent categories—when clinical quality and product repeatability are aligned, brands can scale more predictably and sustain higher margins.